nargenicin A1 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Nargenicin is a macrolide antibiotic that selectively inhibits the growth of
S. aureus, methicilin resistant
S. aureus (MRSA), and
M. luteus (MICs = 0.6, 0.3, and 2.5 μg/ml, respectively) over a panel of 11 Gram-positive and Gram-negative bacteria (MICs = >80 μg/ml). It dose-dependently inhibits
S. aureus DnaE in the presence of DNase I-activated DNA and
E. coli DnaE when used at concentrations of 0.00001-0.1 and 0.01-100 μg/mL, respectively. In murine BV-2 microglial cells, nargenicin (1 μM) inhibits cytokine expression and nitric oxide production induced by LPS. Nargenicin (200 μM), when used in combination with 1,25-dihydroxyvitamin D
3 or all-
trans retinoic acid , reduces cell proliferation by 37-47% and increases cell differentiation by 82-85% in HL-60 human myeloid leukemia cells.
In vivo, nargenicin (50 mg/kg, p.o.) reduces the number of colony-forming units (CFUs) in infected kidneys by 100,000-fold in a murine model of
S. aureus infection.
Verwenden
Nargenicin A1 is an antibiotic with a broad efficacy.
nargenicin A1 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
